ACT1_3A: ACT1, figure 3A

ACT1_3AR Documentation

ACT1, figure 3A

Description

Kaplan-Meier digitized data from ACT1, figure 3A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer.

Usage

ACT1_3A

Format

A data frame of 637 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (amrubicin, topotecan)

Source

von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.

Examples

summary(ACT1_3A)

kmplot(ACT1_3A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.